Table 2. Initial treatment outcomes of visceral leishmaniasis and HIV co-infected patients treated with a combination of liposomal amphotericin B (AmBisome) and miltefosine by MSF in Ethiopia from January 2011 to August 2014, by visceral leishmaniasis treatment history (N = 173).

Initial treatment outcome	Total, n/N (%)	Primary visceral leishmaniasis, n/N (%)	Relapse visceral leishmaniasis, n/N (%)	P
	95% confidence interval	95% confidence interval	95% confidence interval
Cure	145/173 (83.8)	65/83 (78.3)	80/90 (88.9)	0.003a
	(77.6–88.6)	68.3–85.8	80.7–93.9
Death	22/173 (12.7)	17/83 (20.5)	5/90 (5.6)
	(8.5–18.5)	13.2–30.4	2.4–12.4
Parasitological failure	6/173 (3.5)	1/83 (1.2)	5/90 (5.6)
	(1.6–7.4)	0.2–6.5	2.4–12.4

^a Fisher’s exact test.